CHIMPANZEE BIOMEDICAL RESEARCH RESOURCE
黑猩猩生物医学研究资源
基本信息
- 批准号:8356918
- 负责人:
- 金额:$ 256.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-15 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesBehavioralBiocompatible MaterialsBiomedical ResearchCCL7 geneCaringCell LineClinicalComplexFundingGrantHealthHousingHumanImmune systemImmunologicsLaboratoriesLeadershipMaintenanceMedicineModelingNational Center for Research ResourcesPan GenusPhysiologicalPositive ReinforcementsPrincipal InvestigatorProceduresReference ValuesRegistriesResearchResearch InfrastructureResearch PersonnelResourcesRoleScientistSourceTechniquesTrainingU-Series Cooperative AgreementsUnited States National Institutes of HealthUniversity of Texas M D Anderson Cancer Centercomparativecostimprovedlaboratory facilitytoolweb site
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
DESCRIPTION (provided by applicant): This is a competing renewal application of a cooperative agreement supporting the "Chimpanzee Biomedical Research Resource" (CBRR) at the Michale E. Keeling Center for Comparative Medicine and Research (KCCMR) of The University of Texas MD Anderson Cancer Center in Bastrop, TX. The CBRR is a national research resource of 159 chimpanzees housed within the chimpanzee housing complex of the KCCMR. The CBRR is one of only four research resources in the world capable of conducting biomedical research in this species. Over the past 35 years, the CBRR has developed the highly specialized housing facilities, laboratories, management techniques and staff essential for maintaining chimpanzees and conducting research using this important model. The CBRR's primary objectives continue to focus on colony care and maintenance, provision of the infrastructure needed to conduct studies for investigators who need to access chimpanzees, and conducting studies to enhance the research value of chimpanzees. During the current funding period, we developed an informational website to help scientists assess the suitability of chimpanzees as relevant models for their studies and inform the public of the value of chimpanzees. We plan to continue to make available chimpanzee-derived cell lines, antibodies and other biological materials through the Chimpanzee Experimental Tools and Laboratory Reference Value Registry. The CBRR is organized into three functional cores that include the Resource Management Core, the Behavioral Management Core, and the Resource-related Research Core. Studies supported by the CBRR will continue to emphasize the characterization of the chimpanzee immune system and the numerous collaborative behavioral studies through the Behavioral Management Core. These include studies of the physiologic and immunologic consequences of research manipulations on chimpanzees trained to voluntarily cooperate with research procedures compared to untrained chimpanzees that must be anesthetized. The CBRR will continue to maintain its leadership role in the training of chimpanzees to voluntarily participate in research and clinical manipulations using positive reinforcement techniques. Beginning with this period of support, we plan to categorize all chimpanzees within the CBRR using the G-MARC as described in the RFA-RR-10-008. By expanding and improving the availability of CBRR resources, conducting resource-related research, and containing costs, the CBRR will continue to provide a critically important, highly specialized, research resource that addresses human health needs.
该子项目是利用资源的众多研究子项目之一
由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持
并且子项目的主要研究者可能是由其他来源提供的,
包括其他 NIH 来源。 子项目可能列出的总成本
代表子项目使用的中心基础设施的估计数量,
NCRR 赠款不直接向子项目或子项目工作人员提供资金。
描述(由申请人提供):这是一份支持“黑猩猩生物医学研究资源”(CBRR) 的合作协议的竞争续签申请,该协议位于德克萨斯州巴斯特罗普市德克萨斯大学 MD 安德森癌症中心的 Michale E. Keeling 比较医学和研究中心 (KCCMR)。 CBRR 是一个由 159 只黑猩猩组成的国家研究资源,这些黑猩猩居住在 KCCMR 的黑猩猩住宅区内。 CBRR 是世界上仅有的四个能够对该物种进行生物医学研究的研究资源之一。在过去的 35 年里,CBRR 开发了高度专业化的住房设施、实验室、管理技术和人员,这些对于维持黑猩猩和使用这一重要模型进行研究至关重要。 CBRR 的主要目标仍然是集中于群体护理和维护、为需要接触黑猩猩的研究人员提供开展研究所需的基础设施,以及开展研究以提高黑猩猩的研究价值。在当前资助期间,我们开发了一个信息网站,帮助科学家评估黑猩猩作为其研究相关模型的适用性,并向公众宣传黑猩猩的价值。我们计划继续通过黑猩猩实验工具和实验室参考值注册表提供黑猩猩衍生的细胞系、抗体和其他生物材料。 CBRR 分为三个功能核心,包括资源管理核心、行为管理核心和资源相关研究核心。 CBRR 支持的研究将继续强调黑猩猩免疫系统的特征以及通过行为管理核心进行的大量协作行为研究。其中包括对经过训练的黑猩猩进行研究操作的生理学和免疫学后果的研究,这些黑猩猩经过训练可以自愿配合研究程序,与未经训练的必须麻醉的黑猩猩相比。 CBRR 将继续保持其在训练黑猩猩自愿参与使用正强化技术的研究和临床操作方面的领导作用。从这段支持期开始,我们计划使用 RFA-RR-10-008 中所述的 G-MARC 对 CBRR 内的所有黑猩猩进行分类。通过扩大和提高 CBRR 资源的可用性、开展与资源相关的研究以及控制成本,CBRR 将继续提供极其重要、高度专业化的研究资源,以满足人类健康需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTIAN R ABEE其他文献
CHRISTIAN R ABEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTIAN R ABEE', 18)}}的其他基金
ESTABLISH & MAINTAIN CHIMP BIOMEDICAL RES COLONY: IMMUNOLOGY
建立
- 批准号:
8173569 - 财政年份:2010
- 资助金额:
$ 256.57万 - 项目类别:
CHIMPANZEE BIOMEDICAL RESEARCH PROGRAM: VACCINE DVMT
黑猩猩生物医学研究计划:疫苗 DVMT
- 批准号:
8173572 - 财政年份:2010
- 资助金额:
$ 256.57万 - 项目类别:
ESTABLISH & MAINTAIN CHIMP BIOMEDICAL RES COLONY: THERAPEUTIC AGENT DVMT
建立
- 批准号:
8173571 - 财政年份:2010
- 资助金额:
$ 256.57万 - 项目类别:
ESTABLISH & MAINTAIN CHIMP BIOMEDICAL RES COLONY: ANIMAL MODEL
建立
- 批准号:
8173570 - 财政年份:2010
- 资助金额:
$ 256.57万 - 项目类别:
ESTABLISH & MAINTAIN CHIMP BIOMEDICAL RES COLONY: THERAPEUTIC AGENT DVMT
建立
- 批准号:
7961230 - 财政年份:2009
- 资助金额:
$ 256.57万 - 项目类别:
ESTABLISH & MAINTAIN CHIMP BIOMEDICAL RES COLONY: ANIMAL MODEL
建立
- 批准号:
7961229 - 财政年份:2009
- 资助金额:
$ 256.57万 - 项目类别:
CHIMPANZEE BIOMEDICAL RESEARCH PROGRAM: VACCINE DVMT
黑猩猩生物医学研究计划:疫苗 DVMT
- 批准号:
7961231 - 财政年份:2009
- 资助金额:
$ 256.57万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 256.57万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 256.57万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 256.57万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 256.57万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 256.57万 - 项目类别:














{{item.name}}会员




